Fostamatinib Meets Primary Endpoint In Phase 3 Trial In Japan For Treatment Of Chronic Immune Thrombocytopenia

By PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. (“Kissei”), has released positive topline results from its Phase 3 clinical trial in Japan evaluating fostamatinib disodium hexahydrate for the treatment of adult chronic immune thrombocytopenia (ITP). The Phase 3 clinical study (n=34) showed that patients receiving fostamatinib (R788) achieved a stable platelet response significantly higher than patients receiving a placebo control. A stable platel…

Read More